Neurointerventional Devices Market

Neurointerventional Devices Market Forecast and Outlook 2025 to 2035

The global neurointerventional devices market is projected to reach about USD 5.6 billion by 2035, increasing from USD 3.1 billion in 2025. This reflects a compound annual growth rate of 6.1% across the forecast period. Growth is influenced by continued use of minimally invasive approaches for treating cerebrovascular conditions and by higher diagnostic detection of stroke, aneurysms, and other neurovascular disorders.

Between 2025 and 2030, the market is expected to expand as stroke care networks improve referral efficiency and increase the number of facilities equipped to perform endovascular procedures. Several regions invest in imaging units that support rapid assessment of patients presenting with acute neurological symptoms.

Quick Stats for Neurointerventional Devices Market

• Neurointerventional Devices Market Value (2025): USD 3.1 billion
• Neurointerventional Devices Market Forecast Value (2035): USD 5.6 billion
• Neurointerventional Devices Market Forecast CAGR: 6.1%
• Leading Product Type in Neurointerventional Devices Market: Therapeutic Devices
• Key Growth Regions in Neurointerventional Devices Market: Asia Pacific, North America, and Europe
• Top Players in Neurointerventional Devices Market: Terumo Neuro, Medtronic, Stryker, Boston Scientific Corporation, Philips N.V., Penumbra Inc., Johnson & Johnson (CERENOVUS), MicroPort Medical, Rapid Medical, Imperative Care Inc.

This equipment enables timely intervention and encourages broader adoption of devices used in thrombectomy and aneurysm management. Manufacturers refine catheter design, focusing on flexibility, navigability, and compatibility with existing imaging platforms. Hospitals evaluate device portfolios that support consistent performance across varied vascular anatomies.

Between 2030 and 2035, the market is expected to rise further as health systems integrate structured stroke pathways and expand neurointervention capacity. Larger hospitals adopt workflow models that link emergency departments with interventional suites to reduce time-to-treatment metrics.

Device suppliers introduce systems designed to accommodate smaller vessel access and improved aspiration performance. Some institutions evaluate robotic assistance options intended to support precise catheter navigation and reduce procedure variability. The development of flexible contract models for device procurement supports broader access among mid-sized hospitals that are expanding stroke services.

Between 2020 and 2025, the neurointerventional devices market expanded as treatment guidelines in several regions recognized the value of mechanical thrombectomy for selected ischemic stroke cases. Hospitals acquired equipment to align with updated care recommendations, and training programs began to formalize procedural skill development for interventional teams.

Product portfolios diversified to address a range of neurovascular indications, including aneurysm stabilization and arteriovenous malformation management. Improvements in imaging systems contributed to procedural accuracy and supported the adoption of minimally invasive treatment strategies.

Across the forecast period, several factors influence equipment adoption and procurement decisions. Device pricing and reimbursement conditions affect access to neurointerventional procedures, particularly in regions where coverage policies remain limited. Hospitals assess long-term equipment costs, including consumables, maintenance requirements, and compatibility with existing operating room infrastructure. Availability of trained interventional specialists varies by region, affecting procedure volumes and influencing investment decisions for advanced neurovascular systems.

Manufacturers consider production requirements associated with precision catheter engineering, radiopaque material integration, and quality control procedures. Smaller companies may face challenges related to component sourcing, sterility validation, and regulatory compliance. Larger producers maintain specialized manufacturing lines that support consistent device quality and allow for incremental design updates.

Neurointerventional Devices Market Year-over-Year Forecast 2025 to 2035

Between 2025 and 2030, the neurointerventional devices market is projected to expand from USD 3.1 billion to USD 4.2 billion, resulting in a value increase of USD 1.1 billion, which represents 44.0% of the total forecast growth for the decade. This phase of development will be shaped by rising demand for mechanical thrombectomy devices and embolization systems, product innovation in flow-diverter technologies and aspiration catheter designs, as well as expanding integration with AI-assisted imaging platforms and robotic navigation systems. Companies are establishing competitive positions through investment in catheter technology development, minimally invasive procedure capabilities, and strategic market expansion across acute stroke care applications, aneurysm treatment segments, and comprehensive neurovascular intervention programs.

From 2030 to 2035, the market is forecast to grow from USD 4.2 billion to USD 5.6 billion, adding another USD 1.4 billion, which constitutes 56.0% of the overall ten-year expansion. This period is expected to be characterized by the expansion of specialized device innovations, including next-generation stent retrievers and bioactive embolization coils tailored for specific cerebrovascular conditions, strategic collaborations between device manufacturers and healthcare systems, and an enhanced focus on clinical outcome validation and real-world evidence generation practices. The growing emphasis on personalized treatment approaches and evidence-based intervention protocols will drive demand for clinically validated neurointerventional solutions across diverse patient populations.

Neurointerventional Devices Market Key Takeaways

Metric	Value
Market Value (2025)	USD 3.1 billion
Market Forecast Value (2035)	USD 5.6 billion
Forecast CAGR (2025-2035)	6.1%

Why is the Neurointerventional Devices Market Growing?

The neurointerventional devices market grows by enabling hospitals, stroke centers, and neurovascular specialists to access advanced catheter-based technologies that support improved patient outcomes while meeting clinical demand for minimally invasive cerebrovascular interventions.

Healthcare facilities face mounting pressure to reduce surgical complications and improve stroke treatment efficacy, with neurointerventional procedures typically providing 70-85% successful recanalization rates comparable to conventional surgical alternatives, making these technologies essential for competitive clinical positioning in acute neurological care categories.

The medical device industry's need for versatile applications and procedural compatibility creates demand for diverse device types that can provide superior clinical outcomes, maintain consistent performance across different anatomical variations, and ensure regulatory compliance without compromising safety profiles or treatment standards.

Government initiatives promoting stroke awareness and comprehensive neurovascular care drive adoption in emergency medicine, specialized stroke centers, and tertiary healthcare facilities, where neurointerventional device utilization has a direct impact on patient survival rates and functional recovery outcomes.

The healthcare industry's growing focus on time-critical interventions and evidence-based treatment protocols further expands market opportunities, with clinical research demonstrating measurable improvements in modified Rankin Scale scores, reduced disability rates, and enhanced quality of life following mechanical thrombectomy procedures. Device cost constraints and limited reimbursement frameworks may limit accessibility among smaller healthcare facilities and developing regions with limited infrastructure for advanced neurovascular intervention programs and specialized training systems.

Segmental Analysis

The market is segmented by product type, indication, and region. By product type, the market is divided into therapeutic devices and diagnostic devices. Based on indication, the market is categorized into acute ischemic stroke, intracranial aneurysm, arteriovenous malformation, and others. Regionally, the market is divided into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa.

By Product Type, what makes Therapeutic Devices the Dominant Market Category?

The therapeutic devices segment represents the dominant force in the neurointerventional devices market, capturing approximately 66.0% of total market share in 2025. This established product category encompasses solutions featuring mechanical thrombectomy systems, embolization coils, and flow-diverter stents that enable effective treatment of cerebrovascular conditions across all clinical applications. The therapeutic devices segment's market leadership stems from its superior clinical efficacy, with products capable of meeting diverse treatment requirements while maintaining high procedural success rates and operational reliability across all healthcare environments.

Within the therapeutic devices segment, neurothrombectomy devices account for 31.8% of the therapeutic category, driven by increasing adoption of mechanical thrombectomy for acute ischemic stroke treatment and expanding clinical evidence supporting early intervention protocols. These devices offer rapid recanalization capabilities for large vessel occlusions while providing sufficient precision to minimize procedural complications and vessel damage. The diagnostic devices segment accounts for approximately 34.0% of the market, serving healthcare facilities that require advanced imaging catheters and cerebral angiography systems for accurate diagnosis and treatment planning across neurovascular conditions.

Key advantages driving the therapeutic devices segment include:

• Advanced catheter technology with integrated delivery systems that reduce procedural complexity and ensure consistent device performance
• High treatment success rates allowing effective recanalization across different stroke etiologies without significant procedural complications
• Proven clinical compatibility, delivering reliable therapeutic outcomes while maintaining cost-effectiveness against alternative treatment modalities
• Broad regulatory acceptance enabling straightforward product approvals and market entry across multiple healthcare jurisdictions

By Indication, How Does Acute Ischemic Stroke Drive Market Leadership?

Acute ischemic stroke dominates the indication segment with approximately 45.0% market share in 2025, reflecting the critical role of time-sensitive neurovascular interventions in supporting global emergency medicine and comprehensive stroke care operations worldwide. The acute ischemic stroke segment's market leadership is reinforced by increasing stroke incidence rates, expanding mechanical thrombectomy adoption, and rising requirements for rapid recanalization therapies in primary stroke centers across developed and emerging healthcare markets.

Within the acute ischemic stroke segment, mechanical thrombectomy interventions represent 40.4% of the indication category, driven by growing physician preference for endovascular approaches that demonstrate superior outcomes compared to thrombolytic therapy alone. This subsegment benefits from expanding time windows for intervention, comprehensive training programs, and evidence-based protocols that meet specific clinical requirements and treatment guidelines in competitive stroke care environments.

The intracranial aneurysm segment represents the second-largest indication category, capturing 28.0% market share through flow-diverter technologies, coiling systems, and stent-assisted embolization for preventive treatment. Arteriovenous malformation accounts for 14.0% market share, serving specialized neurovascular applications requiring precise embolization techniques. Other indications hold 13.0% market share, including cerebral arterial stenosis and spinal vascular disorders across various clinical scenarios.

Key market dynamics supporting indication growth include:

• Acute ischemic stroke expansion driven by comprehensive stroke system development and mechanical thrombectomy adoption, requiring specialized intervention facilities in emerging markets
• Intracranial aneurysm treatment modernization trends require high-quality flow-diverter technologies for hemodynamic remodeling and aneurysm occlusion consistency
• Integration of advanced imaging technologies enabling precise diagnosis and treatment planning systems
• Growing emphasis on indication-specific solutions driving demand for comprehensive, multi-application device portfolios

What are the Drivers, Restraints, and Key Trends of the Neurointerventional Devices Market?

The market is driven by three concrete demand factors tied to clinical outcomes and healthcare efficiency. First, increasing prevalence of cerebrovascular diseases and stroke incidence creates growing demand for neurointerventional devices, with global stroke cases expanding by 8-10% annually in major developing countries worldwide, requiring comprehensive treatment infrastructure. Second, government initiatives promoting stroke awareness and time-critical intervention protocols drive increased adoption of mechanical thrombectomy systems, with many countries implementing comprehensive stroke care networks for improved patient outcomes by 2030. Third, technological advancements in catheter design and flow-diverter innovations enable more effective and safer neurointerventional procedures that reduce complication rates while improving recanalization success and clinical outcome capabilities.

Market restraints include high device costs and limited reimbursement coverage that can deter healthcare facilities from maintaining comprehensive neurointerventional programs, particularly in developing regions where procurement budgets for advanced medical technologies remain constrained. Limited availability of trained neurointerventional specialists poses another significant challenge, as mechanical thrombectomy procedures demand extensive technical expertise and anatomical knowledge, potentially causing regional disparities in treatment access and procedural outcomes. Infrastructure limitations in emerging healthcare markets create additional challenges for device adoption, demanding ongoing investment in catheter laboratory facilities and comprehensive training programs.

Key trends indicate accelerated adoption in Asia Pacific markets, particularly China and India, where expanding stroke care infrastructure and healthcare investment drive comprehensive neurointerventional device adoption. Technology integration trends toward AI-assisted imaging systems with automated vessel analysis, robotic navigation platforms, and real-world outcome monitoring enable proactive treatment optimization approaches that maximize procedural success and minimize complications. However, the market thesis could face disruption if significant advances in preventive stroke therapies or major changes in treatment paradigms reduce reliance on mechanical intervention technologies.

Analysis of the Neurointerventional Devices Market by Key Countries

Country	CAGR (2025-2035)
China	6.6%
India	6.4%
Brazil	6.2%
USA	6.0%
Germany	5.9%
UK	5.7%
Japan	5.5%

The neurointerventional devices market is expanding steadily, with China leading at a 6.6% CAGR through 2035, driven by rapid stroke care infrastructure development, expanding tertiary hospital networks, and domestic device innovation. India follows at 6.4%, supported by growing neuroscience departments, increasing healthcare expenditure, and rising stroke awareness campaigns. Brazil records 6.2%, reflecting expanding public health funding, increasing stroke treatment capacity, and growing medical device adoption.

The USA posts 6.0%, anchored by mature neurovascular market and strong procedural volumes, innovation in mechanical thrombectomy and flow-diverter technologies. Germany grows at 5.9%, with comprehensive stroke center networks and AI-assisted imaging adoption, strong clinical research capabilities for device validation.

The UK advances at 5.7%, emphasizing expanding NHS neurovascular capabilities and stroke prevention initiatives, growing adoption of minimally invasive intervention protocols, while Japan grows steadily at 5.5%, focusing on high elderly population driving cerebrovascular disease burden, early adoption of advanced neurointerventional technologies.

Why does China Lead in the Neurointerventional Devices Market?

China demonstrates the strongest growth potential in the neurointerventional devices market with a CAGR of 6.6% through 2035. The country's leadership position stems from rapid stroke care infrastructure development, expanding specialized neurovascular centers enabling comprehensive intervention capabilities, and domestic device manufacturing innovation driving cost-effective treatment solutions.

Growth is concentrated in major metropolitan centers, including Beijing, Shanghai, Guangzhou, and Shenzhen, where comprehensive stroke systems and expanding tertiary care facilities are implementing advanced mechanical thrombectomy programs for improved patient outcomes. Distribution channels through public hospital networks, private healthcare facilities, and medical device distributors expand deployment across neurovascular intervention platforms and acute stroke care initiatives. The country's Healthy China initiatives provide policy support for cerebrovascular disease management, including neurointerventional technology adoption.

Key market factors:

• Clinical demand concentrated in tier-1 and tier-2 cities with comprehensive stroke center programs
• Healthcare infrastructure expansion through specialized neurovascular departments and catheter laboratory development
• Comprehensive medical device ecosystem, including domestic manufacturers with proven production capabilities
• Technology integration featuring advanced imaging systems, robotic navigation platforms, and AI-assisted treatment planning technologies

How will India Perform in the Global Neurointerventional Devices Market?

In Mumbai, Delhi, Bangalore, and Chennai, the adoption of neurointerventional devices is accelerating across tertiary care hospitals and specialized neuroscience centers, driven by expanding stroke awareness and comprehensive healthcare investment. The market demonstrates strong growth momentum with a CAGR of 6.4% through 2035, linked to growing neuroscience departments, increasing healthcare expenditure, and expanding medical education programs for interventional neurology.

Indian healthcare facilities are implementing mechanical thrombectomy systems and embolization technologies to enhance stroke treatment capabilities while meeting growing demand in expanding urban demographics and comprehensive healthcare sectors. The country's National Health Mission creates persistent demand for advanced medical technologies, while increasing emphasis on non-communicable disease management drives adoption of cerebrovascular intervention systems.

Key development areas:

• Tertiary hospitals and super-specialty centers leading neurointerventional device adoption with comprehensive stroke programs
• Government healthcare initiatives providing policy support with expanding insurance coverage for stroke interventions
• Technology partnerships between international device manufacturers and Indian healthcare networks are expanding market reach
• Integration of training programs and comprehensive physician education systems

What are the Prospects for the Neurointerventional Devices Market in Brazil?

Brazil's market expansion is driven by diverse healthcare demand, including stroke care modernization in São Paulo and Rio de Janeiro, and neurovascular program development across multiple states. The country demonstrates promising growth potential with a CAGR of 6.2% through 2035, supported by expanding public health funding, increasing stroke treatment capacity, and growing clinical awareness among neurological specialists.

Brazilian healthcare facilities face implementation challenges related to device importation costs and reimbursement limitations, requiring public-private partnerships and support from international medical device companies. However, growing stroke burden and healthcare system development create compelling business cases for neurointerventional device adoption, particularly in urban areas where treatment availability has a direct impact on patient survival outcomes.

Market characteristics:

• Public and private healthcare sectors showing coordinated growth with expanding neurovascular service lines
• Regional expansion trends focused on state capitals and major metropolitan centers
• Future projections indicate the need for comprehensive training infrastructure and technical expertise development programs
• Growing emphasis on domestic distribution networks and regulatory pathway optimization

How will the Neurointerventional Devices Market expand in Germany?

The German market leads in neurointerventional device innovation based on integration with clinical research systems and comprehensive stroke network coordination for enhanced procedural outcomes. The country shows strong potential with a CAGR of 5.9% through 2035, driven by advanced stroke center infrastructure, AI-assisted imaging adoption, and the expansion of specialized neurovascular facilities in major academic centers, including Berlin, Munich, Hamburg, and Frankfurt.

German physicians are adopting evidence-based neurointerventional protocols for stroke treatment optimization and preventive aneurysm management, particularly in regions with comprehensive quality registries and specialized applications demanding strict clinical standards. Technology deployment channels through university hospitals and regional stroke networks expand coverage across neurovascular device manufacturers and specialized intervention-focused operators.

Leading market segments:

• Academic medical centers implementing comprehensive mechanical thrombectomy programs with integrated quality monitoring
• Stroke network partnerships with device manufacturers, achieving high procedural success rates through standardized protocols
• Strategic collaborations between research institutions and clinical operations are expanding evidence generation
• Focus on outcome validation and real-world data collection requirements

How will the Market for Neurointerventional Devices Expand in the USA?

In major healthcare markets including New York, Los Angeles, Chicago, and Houston, comprehensive stroke centers are implementing advanced neurointerventional technologies to modernize existing treatment protocols and improve patient outcomes, with documented case studies showing significant reductions in disability rates through early mechanical thrombectomy.

The market shows strong growth potential with a CAGR of 6.0% through 2035, linked to mature neurovascular device market and high procedural volumes, innovation in next-generation thrombectomy systems and flow-diverter technologies, and emerging value-based care initiatives in major healthcare systems.

American physicians are adopting advanced mechanical thrombectomy devices and specialized embolization systems to enhance treatment efficacy while maintaining quality standards demanded by regulatory authorities and healthcare payers. The country's established stroke care infrastructure creates persistent demand for device innovation and clinical evidence generation that integrates with existing treatment algorithms.

Market development factors:

• Comprehensive stroke centers and tertiary hospitals leading neurointerventional device adoption across USA
• Quality improvement programs providing clinical outcome monitoring for procedural optimization
• Strategic partnerships between American device manufacturers and international technology companies are expanding innovation capabilities
• Emphasis on FDA approval pathways and clinical trial evidence across neurovascular applications

What is the Outlook for the Neurointerventional Devices Market in the UK?

UK's neurointerventional devices market demonstrates comprehensive healthcare system integration focused on stroke prevention strategies and mechanical thrombectomy adoption, with documented implementation of evidence-based protocols achieving improved functional outcomes across regional stroke networks.

The country maintains steady growth momentum with a CAGR of 5.7% through 2035, driven by expanding NHS neurovascular capabilities and stroke prevention initiatives, growing adoption of minimally invasive intervention protocols, and clinical emphasis on outcome measurement that aligns with National Institute for Health and Care Excellence guidelines.

Major healthcare markets, including London, Manchester, Birmingham, and Edinburgh, showcase advanced deployment of mechanical thrombectomy systems where stroke centers integrate seamlessly with emergency medicine networks and comprehensive quality monitoring programs.

Key market characteristics:

• NHS stroke networks driving device adoption with emphasis on clinical guidelines and outcome benchmarking
• Regional coordination enabling standardized treatment protocols with comprehensive patient pathway optimization
• Technology collaboration between UK healthcare trusts and international device manufacturers is expanding clinical capabilities
• Emphasis on cost-effectiveness analysis and health technology assessment methodologies

How will an Expanding Aging Population Generate Demand for Neurointerventional Devices in Japan?

Japan's neurointerventional devices market demonstrates mature and technology-focused landscape, characterized by sophisticated integration of advanced catheter technologies with established neurovascular care protocols across comprehensive stroke centers, academic hospitals, and specialized neurological facilities.

The country shows steady growth momentum with a CAGR of 5.5% through 2035, driven by high elderly population and increasing cerebrovascular disease burden, early adoption of minimally invasive neurointerventional technologies. Japan's emphasis on procedural precision and safety standards creates requirements for high-quality device technologies that support comprehensive stroke care initiatives and regulatory compliance requirements in clinical operations.

The market benefits from strong partnerships between international device manufacturers and domestic healthcare systems, creating comprehensive clinical ecosystems that prioritize patient outcomes and evidence-based treatment programs. Healthcare facilities in major urban regions showcase advanced neurointerventional implementations where mechanical thrombectomy procedures achieve high success rates through integrated quality assurance programs.

Key market characteristics:

• Academic medical centers and stroke centers driving advanced device adoption with emphasis on clinical excellence and safety
• Quality assurance partnerships enabling comprehensive procedural monitoring with validated outcome metrics
• Technology collaboration between Japanese healthcare institutions and international device manufacturers is expanding clinical capabilities
• Emphasis on preventive neurovascular care and continuous quality improvement methodologies

What is the Outlook for the Market’s Expansion in South Korea?

South Korea's neurointerventional devices market reflects advanced healthcare infrastructure and rapid technology adoption, with comprehensive stroke center networks in Seoul, Busan, and Incheon implementing state-of-the-art mechanical thrombectomy programs. The market benefits from strong government support for healthcare innovation, high physician expertise in interventional neurology, and growing medical device manufacturing capabilities.

South Korean hospitals demonstrate sophisticated procedural volumes with advanced imaging integration, robotic navigation systems, and real-time outcome monitoring platforms that optimize treatment protocols. The country's National Health Insurance system provides comprehensive reimbursement coverage for neurointerventional procedures, driving consistent device adoption across public and private healthcare sectors while maintaining high clinical standards.

Europe Market Split by Country

The neurointerventional devices market in Europe is projected to grow from USD 270.0 million in Germany in 2025, maintaining a 28.0% market share, supported by its extensive stroke center infrastructure, advanced neurovascular facilities, and comprehensive clinical networks serving major European healthcare markets.

The UK follows with USD 193.0 million and a 20.0% share in 2025, driven by comprehensive NHS stroke programs in major regions implementing advanced mechanical thrombectomy adoption. France holds USD 145.0 million with a 15.0% share through the ongoing development of neurovascular intervention networks and stroke care modernization.

Italy commands USD 116.0 million with a 12.0% share, while Spain accounts for USD 87.0 million with a 9.0% share in 2025. The Rest of Europe region maintains USD 155.0 million with a 16.0% collective share, attributed to increasing neurointerventional device adoption in Nordic countries and emerging Eastern European healthcare markets implementing comprehensive stroke care programs.

Competitive Landscape of the Neurointerventional Devices Market

The neurointerventional devices market features approximately 15-20 meaningful players with moderate to high concentration, where the top three companies control roughly 35-40% of global market share through established product portfolios and extensive hospital relationships. Competition centers on clinical evidence generation, procedural innovation, and comprehensive physician training rather than price competition alone.

Market leaders include Terumo Neuro, Medtronic, and Stryker, which maintain competitive advantages through comprehensive neurointerventional device portfolios, global distribution networks, and deep expertise in the neurovascular intervention and stroke care sectors, creating high switching costs for healthcare providers.

These companies leverage established neurology department relationships and ongoing clinical education services to defend market positions while expanding into adjacent cerebrovascular applications and emerging treatment modalities.

Terumo Neuro holds the highest global market share at 15.2% in 2025, reinforced by its recent launch of the SOFIA 88 Catheter in the USA and the establishment of the Aneurysm Treatment Alliance across EMEA regions, demonstrating strong commercial execution and clinical partnership development.

Challengers encompass Boston Scientific Corporation and Philips N.V., which compete through specialized catheter technologies and advanced imaging integration capabilities in key neurovascular markets. Medical device specialists, including Penumbra Inc., Johnson & Johnson (CERENOVUS), and MicroPort Medical, focus on specific device categories or treatment applications, offering differentiated capabilities in aspiration systems, embolization technologies, and flow-diverter innovations for targeted clinical segments.

Regional players and emerging medical device companies create competitive pressure through innovative catheter designs and rapid regulatory approval strategies, particularly in high-growth markets including China and India, where local manufacturing capabilities provide advantages in hospital relationships and cost positioning. Market dynamics favor companies that combine advanced device engineering with comprehensive physician training programs that address the complete treatment pathway from emergency stroke diagnosis through post-procedural patient management and long-term outcome monitoring.

Key Players in the Neurointerventional Devices Market

• Terumo Neuro
• Medtronic
• Stryker
• Boston Scientific Corporation
• Philips N.V.
• Penumbra Inc.
• Johnson & Johnson (CERENOVUS)
• MicroPort Medical
• Rapid Medical
• Imperative Care Inc.
• Acandis GmbH
• MicroVention (Terumo)
• Balt Extrusion
• Asahi Intecc
• Perflow Medical

Scope of the Report

Items	Values
Quantitative Value (USD Million)s	USD 3.1 Billion
Product Type	Therapeutic Devices, Diagnostic Devices
Indication	Acute Ischemic Stroke, Intracranial Aneurysm, Arteriovenous Malformation, Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East & Africa
Country Covered	China, India, Brazil, USA, Germany, UK, Japan, South Korea, and 40+ countries
Key Companies Profiled	Terumo Neuro, Medtronic, Stryker, Boston Scientific Corporation, Philips N.V., Penumbra Inc., Johnson & Johnson (CERENOVUS), MicroPort Medical, Rapid Medical, Imperative Care Inc.
Additional Attributes	Dollar sales by product type and indication categories, regional adoption trends across Asia Pacific, Europe, and North America, competitive landscape with medical device manufacturers and specialized neurovascular companies, clinical requirements and procedural specifications, integration with stroke care networks and comprehensive cerebrovascular treatment programs.

Neurointerventional Devices Market by Segments

• Product Type :

  • Therapeutic Devices
  • Diagnostic Devices

• Indication :

  • Acute Ischemic Stroke
  • Intracranial Aneurysm
  • Arteriovenous Malformation
  • Others

• Region :

  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • ASEAN
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe
  • North America
    • USA
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Union
    • Rest of Middle East & Africa